13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $8M | -$65M | 73.3% | -975.9% | -$47M | — | $20M |
| 2024 | $19M | -$132M | 85.1% | -758.2% | -$20M | — | $25M |
| 2023 | $31M | -$88M | 89.0% | -311.6% | -$80M | — | $40M |
| 2022 | $30M | -$87M | 86.5% | -302.0% | -$68M | — | $45M |
| 2021 | $7M | -$91M | 30.3% | -1327.1% | -$52M | — | $27M |
| 2020 | $6M | -$51M | 20.8% | -785.4% | -$39M | $11M | $22M |
| 2019 | $4M | -$161M | 4.1% | -2627.3% | -$98M | — | $34M |
| 2018 | $6M | -$133M | 52.7% | -1378.3% | -$102M | $30M | — |
| 2017 | $2M | -$69M | 28.3% | -3230.0% | -$56M | — | $20M |
| 2016 | — | -$48M | — | — | -$35M | — | $30M |
| 2015 | — | -$21M | — | — | -$21M | — | $10M |
| 2014 | — | -$9M | — | — | — | — | $11M |
| 2013 | — | -$5M | — | — | — | — | $10M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $2M | -$20M | 80.2% | -1111.8% | -$18M | — | $29M |
| Dec '25 | $1M | -$20M | 58.9% | -1755.5% | -$13M | — | $20M |
| Sep '25 | $3M | -$15M | 83.7% | -519.8% | -$11M | — | $25M |
| Jun '25 | $2M | -$15M | 71.0% | -1035.9% | -$10M | — | $25M |
| Mar '25 | $1M | -$15M | 65.2% | -1242.9% | -$13M | — | $30M |
| Dec '24 | $9M | -$97M | 92.3% | -1082.1% | -$9M | — | $25M |
| Sep '24 | $4M | -$8M | 85.0% | -240.9% | $22M | — | $48M |
| Jun '24 | $3M | -$11M | 77.4% | -464.7% | -$12M | — | $23M |
| Mar '24 | $2M | -$17M | 66.3% | -789.4% | -$21M | — | $36M |
| Dec '23 | $18M | -$1M | 95.9% | -23.0% | -$7M | — | $40M |
| Sep '23 | $9M | -$29M | 90.9% | -340.2% | -$25M | — | $39M |
| Jun '23 | $2M | -$30M | 44.2% | -1702.2% | -$21M | — | $31M |
| Mar '23 | $3M | -$28M | 68.0% | -1183.5% | -$27M | — | $45M |
| Dec '22 | $8M | -$28M | 88.7% | -375.1% | -$19M | — | $45M |
| Sep '22 | $19M | -$20M | 95.1% | -109.8% | -$8M | — | $62M |
| Jun '22 | $2M | -$21M | 30.1% | -1374.0% | -$20M | — | $68M |
| Mar '22 | $1M | -$19M | 20.5% | -1301.2% | -$21M | — | $36M |
| Dec '21 | $2M | -$23M | 23.5% | -1525.2% | -$17M | — | $27M |
| Sep '21 | $2M | -$21M | 33.8% | -1223.3% | -$11M | — | $54M |
| Jun '21 | $2M | -$18M | 30.8% | -987.2% | — | $11M | $113M |
How the market has priced ACRS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Aclaris Therapeutics, Inc.'s revenue has grown 3.8% per year. These are computed facts, not advice.
As of FY2025, Aclaris Therapeutics, Inc. reported — of total debt against $20M of cash.
In FY2025, gross margin was 73.3%, operating margin -975.9%, and net margin -829.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.